Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dharmais National Cancer Center Hospital
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT) between 2011 and 2016.
The primary end points are overall survival (OS) and progression free survival (PFS) with Kaplan Meier.
This study was approved by Ethical Committee in Dharmais National Cancer Hospital.
Age
Any age
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
IIIB/C and IV stage of breast cancer
received neoadjuvant hormonal therapy or neoadjuvant chemotherapy
had first and second biopsy (surgery) within 6 months
You may not be if
had mastectomy before treatment
pregnant
disagree to enter the study
had been given hormonal therapy or chemotherapy before study
had contra-indication of SOB for pre-menopausal patients
Clareo Health | Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
